Mitsuaki Kuwano

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 114(Granted Patents)

Location History:

Toyonaka, JP (1995 - 1999)
Ikoma, JP (2002 - 2011)
Osaka, JP (2000 - 2021)

Company Filing History:

10 out of 281

Santen Pharmaceutical Co., Ltd.

Years Active: 1995-2021

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11166974 - Ophthalmic solution comprising Diquafosol (2021-11-09),

2. 10632139 - Ophthalmic solution comprising diquafosol (2020-04-28),

3. 10071113 - Ophthalmic solution comprising diquafosol (2018-09-11),

4. 9486529 - Ophthalmic solution comprising diquafosol (2016-11-08),

5. 7923034 - Process for producing microparticles (2011-04-12),

6. 7455855 - Delivering substance and drug delivery system using the same (2008-11-25),

7. 6582718 - Cyclosporin compositions (2003-06-24),

8. 6479627 - Aqueous preparation of lactoferrin having improved stability (2002-11-12),

9. 6015810 - Aqueous ophthalmic solution containing apafant as active ingredient (2000-01-18),

10. 5951971 - Ophthalmic compositions (1999-09-14),

11. 5559157 - Ophthalmic compositions containing vitamin E or ester thereof as an (1996-09-24),

12. 5458873 - Carboxyvinyl polymer having Newtonian viscosity (1995-10-17),

Title: Mitsuaki Kuwano: Innovator in Ophthalmic Solutions

Introduction

Mitsuaki Kuwano is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of ophthalmology, particularly through his innovative formulations of ophthalmic solutions. With a total of 12 patents to his name, Kuwano's work has had a substantial impact on the treatment of eye conditions.

Latest Patents

Kuwano's latest patents focus on the development of Diquafosol ophthalmic solutions. These solutions incorporate a chelating agent at a concentration of 0.0001 to 1% (w/v). His research addresses the formation of insoluble precipitates that can occur during the storage of Diquafosol ophthalmic solutions. Additionally, he has tackled the deterioration of filtration performance during the production process. The inclusion of a chelating agent has been shown to reduce eye irritation and enhance the preservative effectiveness of the solution. This innovation ensures that the physicochemical properties remain stable throughout production, distribution, and patient storage.

Career Highlights

Throughout his career, Mitsuaki Kuwano has worked with notable companies in the pharmaceutical industry. He has been associated with Santen Pharmaceutical Co., Ltd. and Novartis AG. His experience in these organizations has contributed to his expertise in developing effective ophthalmic treatments.

Collaborations

Kuwano has collaborated with several professionals in his field, including Yoichi Kawashima and Akiko Sakatani. These partnerships have facilitated the advancement of his research and the successful implementation of his inventions.

Conclusion

Mitsuaki Kuwano's contributions to ophthalmic solutions demonstrate his commitment to improving patient care through innovative research. His patents reflect a deep understanding of the challenges in ophthalmology and a dedication to finding effective solutions.

This text is generated by artificial intelligence and may not be accurate.